Recent advances in treatment of youth with Type 1 diabetes: better care through technology
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
While treatment of Type 1 diabetes mellitus (T1DM) in children and adolescents is especially difficult, recent technological advances have provided new therapeutic options to clinicians and patients. The urgency to achieve strict diabetes control and the introduction of new and improved insulin pumps have been accompanied by a marked increase in use of continuous subcutaneous insulin infusion (CSII) therapy in youth with diabetes. Results of clinical outcome studies indicate that CSII provides a safe and effective alternative to multiple daily injection (MDI) therapy, even when employed in a regular clinic setting in a large number of children. The safety and efficacy of CSII is further enhanced by the introduction of lispro and aspart insulin. The sharper peaks and shorter duration of action of these very rapid‐acting insulin analogues provides a means to achieve better control of post‐prandial hyperglycaemia with less late post‐prandial and nocturnal hypoglycaemia. Glargine insulin, a soluble and essentially peakless long‐acting insulin analogue, may provide a better basal insulin for MDI regimens, but there are limited published data with this agent in children with T1DM. A number of systems for pulmonary delivery of insulin are in development and preliminary results of Phase III studies have been promising. Like CSII, inhaled insulin allows the child to take bolus insulin doses before each meal without having to take a premeal injection. A major obstacle to effective treatment is that self‐monitoring of three to four blood glucose levels a day often misses the marked glycaemic excursions that characterize T1DM in young patients. On the other hand, new continuous glucose sensing systems provide a wealth of data that can be used to optimize basal and bolus therapy, regardless of how insulin is administered. Even more important, we may finally be at the threshold of development of a practically applicable artificial pancreas. Diabet. Med. 18, 864–870 (2001)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420603 · Cited by 1,534
The Diabetes Control and Complications Trial Research Group (1995) · Diabetes · doi:10.2337/diab.44.8.968 · Cited by 1,301
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739
Davis, E. A., Keating, B., Byrne, G. C., Russell, M., & Jones, T. W. (1997) · Diabetes Care · doi:10.2337/diacare.20.1.22 · Cited by 273
Bode, B. W., Gross, T. M., Thornton, K. R., & Mastrototaro, J. J. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00113-8 · Cited by 232
Bolli, G. B., & Owens, D. R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02546-0 · Cited by 186
Cited by
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus
Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., & Siebenhofer, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009122.pub2 · Cited by 299
Heller, S., White, D., Lee, E., Lawton, J., Pollard, D., Waugh, N., Amiel, S., Barnard, K., Beckwith, A., Brennan, A., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21200 · Cited by 73
“insulin continuously under the skin via a small plastic tube and cannula [continuous subcutaneous insulin infusion (CSII)].(6,7) These devices are filled with reservoirs of quick-acting insulin only (usually an insulin analogue), which provides insulin replacement by delivering both the mealtime and background insulin.”
BackgroundThethi, T. K., Rao, A., Kawji, H., Mallik, T., Yau, C. L., Christians, U., & Fonseca, V. (2010) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2009.03.002 · Cited by 53
Llewellyn, S., Procter, R., Harvey, G., Maniatopoulos, G., & Boyd, A. (2014) · Health Services and Delivery Research · doi:10.3310/hsdr02230 · Cited by 43
“In particular, it is suggested that the continuous infusion of insulin provides not only improvement in metabolic control, but also increased physiological and psychological well-being.(189,200) Other benefits include improved patient outcomes [e.”
Background
Metadata
- Authors
- Tamborlane, W. V., Bonfig, W., & Boland, E.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 2001-11
- Volume
- 18
- Issue
- 11
- Pages
- 864-870
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2044153289
- Cited by
- 71
- References
- 8
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances in treatment of youth with Type 1 diabetes: better care through technology. https://app.cochat.ai/papers/10.1046/j.1464-5491.2001.00626.x
- The paper
- Tamborlane, W. V., Bonfig, W., & Boland, E. (2001). Recent advances in treatment of youth with Type 1 diabetes: better care through technology. Diabetic Medicine. https://doi.org/10.1046/j.1464-5491.2001.00626.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.